NewsBenzinga据报道,CRISPR Therapeutics 报告称,接受 Zugo-Cel 治疗的系统性硬化症患者中有 83% 在第 3 个月达到 rCRISS-25 应答,而全部 9 名肌炎患者均达到中度或显著 TIS 应答 据报道,CRISPR Therapeutics 报告称,接受 Zugo-Cel 治疗的系统性硬化症患者中有 83% 在第 3 个月达到 rCRISS-25 应答,而全部 9 名肌炎患者均达到中度或显著 TIS 应答 Benzinga 2026.11.09 08:11 (GMT+0) Open on Benzinga Other news What Are Wall Street Analysts' Target Price for Lumentum Holdings Stock? Texas Pacific Land Stock: Analyst Estimates & Ratings Keybanc Reiterates Sector Weight on NVIDIAto Sector Weight Top 3 Tech Stocks That May Fall Off A Cliff This Month Truist Securities Maintains Hold on BILL Holdings, Raises Price Target to $66 Nvidia’s China Exit Could Trigger a Bull-Bear Showdown: 6 Leveraged ETFs to Watch Wednesday